Mounjaro reimbursement: what Dutch insurance does and does not pay in 2026

Mounjaro reimbursement depends entirely on what it was prescribed for. For type 2 diabetes it is covered by the Dutch basic insurance package under conditions. If you use it to lose weight, you pay yourself, and in practice that comes to roughly 250 to 400 euro per month.

That difference is large enough to decide a whole treatment path.

What the comparison articles leave out is the bill that follows: people who pay themselves usually also fall outside the monitoring that runs automatically with a prescribed indication.

Is Mounjaro reimbursed by Dutch health insurance?

For type 2 diabetes usually yes, for obesity without diabetes no. Insurers apply further conditions: typically type 2 diabetes, a BMI above 30, and insufficient result from earlier blood-sugar-lowering drugs. If you meet those, it comes from the basic package, with your deductible as the first bill.

The deductible stands at 385 euro in 2026. For medicines there is also a statutory maximum personal contribution of 250 euro per person per year.

The file is moving. Zorginstituut Nederland has advised widening the reimbursement conditions for tirzepatide to people with type 2 diabetes and a very high cardiovascular risk, from May 2026. Conditions therefore change yearly, and your own policy is what ultimately decides.

Always check with your own insurer before assuming anything.

What do the different weight-loss drugs cost?

Without reimbursement the monthly amounts run between roughly 70 and 400 euro. The differences are large, and the cheapest drugs are also the least effective. The Dutch Farmacotherapeutisch Kompas describes the registered indication per drug, which determines whether reimbursement comes into play at all.

The common thread is simple. Reimbursement follows the registered indication, not your goal.

A fuller comparison of what each drug does sits in weight-loss medication.

Why is Mounjaro not reimbursed for weight loss?

Because in the Netherlands it is not in the basic package for that indication, while the target group is enormous. According to RIVM figures roughly half of Dutch adults are overweight and more than one in seven has obesity. Reimbursing a drug of several hundred euro a month for that group would hit the collective premium hard.

That is a political trade-off, not a medical judgement on the drug.

Its effectiveness is not in dispute. In SURMOUNT-1 participants lost an average of 15.0%, 19.5% and 20.9% of body weight after 72 weeks at 5, 10 and 15 mg respectively, against 3.1% on placebo (Jastreboff et al., 2022).

For comparison, semaglutide reached 14.9% after 68 weeks in STEP 1 (Wilding et al., 2021). The difference between the two drugs is worked out in Ozempic or Mounjaro.

What does paying yourself mean for your monitoring?

That you have to arrange it yourself. Someone who receives Mounjaro through a GP or internist for diabetes is automatically in a monitoring schedule with periodic blood tests. Someone paying for it through an online clinic often sits outside that structure, while the drug is identical.

That is the most overlooked part of this whole subject, to my mind.

It concerns values such as HbA1c for the sugar system, the liver value ALT, and the pancreatic values. The Dutch health information service Thuisarts advises contacting your GP about new or persistent complaints during medication use, whatever route you obtained the drug through.

Our GLP-1 baseline panel is built for exactly that situation, assessed by a BIG-registered doctor.

What happens financially if you stop?

The monthly costs end, but so does the effect. In STEP 4 the group switched to placebo gained 6.9%, while the group that continued lost a further 7.9% (Rubino et al., 2021).

That makes the cost question different from a course of treatment. These are drugs that work as long as you take them.

If you are budgeting for six months, budget for longer.

Where is the best place to start?

With your GP, even if you intend to pay yourself. They can assess whether there is an indication that is reimbursed, and whether there are reasons not to start these drugs at all. Only then do you know whether the reimbursement question applies to you in the first place.

What strikes me is how many people skip that step because they assume the answer is no.

Ask before you plan a year of monthly payments.

References

• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. PMID 35658024
• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. PMID 33567185
• Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021. PMID 33755728
• Farmacotherapeutisch Kompas, monographs for tirzepatide, semaglutide, liraglutide and naltrexone with bupropion.
• RIVM, figures on overweight and obesity among adults in the Netherlands.
• Thuisarts, information on complaints during medication use.

Every blood test result includes a professional assessment from a BIG-registered doctor. For treatment decisions, discuss your results with your GP.